1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PKU Healthcare Corp. Ltd. Class A

PKU Healthcare Corp. Ltd. Class A

SSZSE:000788
5.70
CNY
0.00
(0.00%)
0.10EPS
50.82P/E
2.91BMarket Cap
PKU Healthcare Corp. Ltd. Class A
SZSE:000788
(Shenzhen Stock Exchange)

Recent

price

5.70

P/E

ratio

50.82

div

yld

3.66%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.01
3.23
3.32
3.86
4.18
3.21
3.3
3.76
4.1
4.21
3.32
3.75
3.49
3.68
3.46
2.49
1.94
Revenue per Share
0.48
0.19
0.13
0.13
-0.05
0.04
0.02
0.06
0.08
0.08
0.07
0.07
0.09
0.07
0.23
0.14
0.1
Basic EPS, GAAP
-0.32
-0.66
-0.49
-0.32
-0.09
0.41
-0.22
-0.06
0.3
-0.08
-0.21
0.02
0.41
0.1
0.52
0.57
- -
Free Cash Flow per Basic Share
0.06
0.16
0.16
0.15
0.19
0.12
0.04
0.01
0.03
0.04
0.02
0.03
0.05
0.01
0.08
0.06
0.21
Dividend per Share
1.6
1.68
1.78
1.92
1.86
1.9
1.92
1.97
2.04
2.1
2.18
2.25
2.32
2.39
2.54
2.62
2.55
Book Value per Share
1.35
1.44
1.54
1.65
1.44
1.89
1.91
1.96
2
2.03
2.04
2.06
2.1
2.17
2.3
2.44
2.39
Tangible Book Value per Share
601
606
586
600
542
626
628
571
565
596
596
596
596
596
596
596
596
Basic Weighted Avg Shares
1,810
1,956
1,948
2,316
2,266
2,011
2,070
2,146
2,316
2,509
1,977
2,237
2,077
2,194
2,060
1,482
1,153
Sales/Revenue/Turnover
9.59
7.76
5.69
5.37
3.72
-9.72
3.04
3.07
3.76
4.4
5.45
5.65
4.58
4.46
10.01
10.68
12.33
Operating Margin (%)
58
46
47
60
112
119
14
17
16
17
19
43
48
51
53
54
- -
Depreciation Expense
288
115
76
78
-27
25
13
34
45
50
39
43
56
44
138
83
57
Net Income, GAAP
6.8
16.93
22.62
23.26
- -
65.34
66.56
15.16
30.96
24.3
25.49
30.3
21.49
40.3
19.94
19.27
18.89
Effective Tax Rate (%)
15.94
5.89
3.91
3.37
-1.2
1.24
0.61
1.6
1.95
2
1.98
1.93
2.68
2.02
6.7
5.59
4.96
Profit Margin (%)
442
152
-284
-316
-634
883
892
937
965
1,008
1,005
1,074
1,046
1,085
1,196
1,294
1,219
Working Capital
271
510
539
562
545
- -
- -
- -
- -
- -
86
67
42
24
11
4
64
LT Debt
972
1,040
1,100
1,178
1,133
1,130
1,138
1,171
1,209
1,246
1,291
1,335
1,377
1,421
1,514
1,561
1,517
Total Equity
8.69
6.05
3.13
2.61
- -
-0.62
0.53
2.58
3.36
3.86
2.61
2.63
3.54
3.12
9.1
7.37
5.61
Return on Invested Capital (%)
24.35
7.8
4.4
3.87
- -
2.49
1.27
3.19
3.99
4.16
3.21
3.53
4.32
3.16
9.17
5.36
3.6
Return on Capital (%)
39.22
11.91
7.38
7.07
-2.41
2.23
1.1
2.96
3.78
4.07
3.07
3.27
4.08
3.16
9.4
5.39
3.72
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
20
23
25
LT Borrowings
- -
- -
- -
LT Finance Leases
4
66
64
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
596
596
596
Market Capitalization
3,641
3,552
2,908

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,662
1,476
1,544
Cash, Cash Equivalents & STI
909
966
1,030
Accounts Receivable, Net
487
268
246
Inventories
135
115
121
Total Current Liabilities
369
314
325
Payables & Accruals
- -
- -
- -
ST Debt
20
23
25
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.29%
3.87%
3.11%
Free Cash Flow
117.58%
384.24%
9.77%
Net Income, GAAP
33.39%
37.98%
-39.94%
Sales/Revenue/Turnover
-2.08%
-4.51%
-28.04%
Total Cash Common Dividend
105.96%
215.66%
-21.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
494
514
526
526
2,060
2025
502
455
- -
251
1,482
2026
215
232
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.07
0.07
0.01
0.23
2025
0.08
0.09
- -
-0.09
0.14
2026
0.05
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
0.05
0.08
2025
- -
0.03
- -
0.01
0.06
2026
0.17
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PKU HealthCare Corp., Ltd. (000788.SZ) engages in the research, development, production, and sale of chemical pharmaceutical preparations; pharmaceutical distribution; and medical services in China. The company, founded in 1965 as the predecessor Southwest Synthetic Pharmaceutical Factory and listed on the Shenzhen Stock Exchange in 1997, is headquartered in Chongqing and focuses on core therapeutic areas including anti-infectives, analgesics, psychiatrics, and chronic diseases, offering products such as injectable ceftriaxone sodium, meropenem for injection, moxifloxacin hydrochloride injection, clindamycin hydrochloride palmitate granules, naphthymidone capsules, celecoxib capsules, dexketoprofen tablets and capsules, buspirone hydrochloride tablets, olanzapine tablets, ondansetron hydrochloride tablets, as well as categories covering cardiovascular and cerebrovascular, antimicrobial, antipyretic and analgesic, digestive system, anti-tumor, psychoneurological, immunosuppressive, oncology, anti-allergic, blood sugar regulation, and mental disorder treatments. In late 2024, the company underwent a major ownership change through the acquisition of its controlling stake by investor Xu Xiren via entities including New Advantage International and Zhongbei Jiuzhou, leading to the separation from prior Peking University branding affiliations and positioning Xu as actual controller after Ping An's exit; however, in October 2025, Xu Xiren was detained in a criminal probe related to the transaction, which involved transferring equity and significant debt, prompting ongoing leadership and operational disruptions including director changes and retiree protests. Recent developments also encompass approval for ondansetron hydrochloride tablets passing generic drug consistency evaluation in April 2025 and plans to establish a public welfare foundation with 5 million yuan investment.